(MENAFN- EIN Presswire)
Emergen Research Logo
The therapeutics market for cystic fibrosis has been growing rapidly due to the emergence of targeted drugs, raising awareness among patients
VANCOUVER, BRITISH COLUMBIA, CANADA, January 21, 2025 /EINPresswire / -- The cystic fibrosis therapeutics market is expected to grow from an estimated USD 10.52 billion in 2024 to USD 37.60 billion in 2033, at a CAGR of 15.20%. The global cystic fibrosis therapeutics market is witnessing significant growth, driven by groundbreaking advancements in treatment, increased awareness among patients, and supportive regulatory policies. The introduction of CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulators has revolutionized care, targeting the root cause of the disease and enabling personalized therapies.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @
Key Drivers of Market Growth
CFTR modulators, such as Vertex Pharmaceuticals' Trikafta, have demonstrated remarkable efficacy, improving lung function and reducing pulmonary exacerbations. The increased adoption of these therapies, particularly in North America and Europe, has fueled demand. Recent FDA approvals, including new formulations targeting rare CFTR mutations, and EMA's expanded approval of Kaftrio for younger patients, highlight the growing accessibility of these life-changing treatments.
The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, including AbbVie and Gilead Sciences, are investing heavily in R&D to develop advanced formulations that improve drug delivery and efficacy.
Innovative Products and Expanding Therapeutic Options
Vertex Pharmaceuticals remains the leader in CFTR modulators, with products such as Kalydeco, Orkambi, and Symdeko contributing significantly to market growth. The company recorded a 20% revenue increase in 2023, driven by its robust CF portfolio. Meanwhile, inhalation therapies, such as Novartis' tobramycin inhalation powder, are gaining popularity due to their targeted delivery to the lungs and enhanced patient compliance.
Emerging players and partnerships are also expanding treatment options. AbbVie's recent phase III trial results for a novel CFTR potentiator underscore the potential for next-generation therapies, while collaborations with research institutions are paving the way for treatments addressing a broader range of CF mutations.
Challenges in Accessibility and Cost
Despite these advancements, challenges remain. High treatment costs, with some therapies priced at hundreds of thousands of dollars annually, pose significant barriers for patients, even in well-funded healthcare systems. Advocacy groups are urging policy reforms to reduce out-of-pocket expenses, but progress has been slow.
In emerging markets, constrained healthcare budgets and limited awareness further hinder access to advanced therapies. Companies are exploring patient assistance programs and tiered pricing models to address these issues, but widespread adoption has yet to materialize.
For more informative information, please visit us @
Cystic Fibrosis Therapeutics Top Companies and Competitive Landscape
The market for CF therapeutics is quite competitive and involves several key players as an attempt to develop innovative treatment options to enhance patient outcomes. Those who are ahead in this list include Vertex Pharmaceuticals, AbbVie Inc., Genentech-a member of the Roche Group, Gilead Sciences, Inc., Novartis AG, Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Ltd., Viatris Inc., Proteostasis Therapeutics, Inc., and Alcresta Therapeutics. Such companies are aggressively involved in research and development, strategic alliances, and partnerships that help them upgrade their product lines and increase their market share.
Vertex Pharmaceuticals continues to dominate the market with CFTR modulator therapies: Trikafta, Symdeko, Orkambi, and Kalydeco have set a new benchmark in cystic fibrosis treatment. Moreover, in June 2024, Vertex announced its partnership with Moderna Therapeutics, which aims to advance mRNA-based treatments of cystic fibrosis, thus reiterating the company's awareness of cutting-edge techniques applied in therapeutic development. Another company making strides is Genentech, which continues to be a cornerstone in the management of mucus viscosity in CF patients with its Pulmozyme (dornase alfa) inhalation therapy.
Some of the key companies in the global Cystic Fibrosis Therapeutics Market include:
Vertex Pharmaceuticals
AbbVie Inc.
Gilead Sciences, Inc.
Novartis AG
Genentech, Inc.
Chiesi Farmaceutici
Teva Pharmaceutical Industries Ltd.
Cipla Ltd.
AstraZeneca
F. Hoffmann-La Roche Ltd.
Cystic Fibrosis Therapeutics Latest Industry Updates
In January 2024, Vertex Pharmaceuticals announced FDA approval for expanded use of Trikafta to include children aged 2 years and above, broadening the patient population that can benefit from the therapy.
In February 2024, AbbVie acquired a stake in a biotech firm focused on gene therapy for cystic fibrosis, aiming to diversify its treatment options.
In March 2024, Novartis launched a next-generation inhaled antibiotic therapy for cystic fibrosis patients, enhancing treatment adherence and efficacy.
Buy the full research report at @
Cystic Fibrosis Therapeutics Market Segmentation Analysis
By Drug Class Outlook (Revenue, USD Million; 2020-2033)
CFTR Modulators
Pancreatic Enzyme Supplements
Mucolytics
Bronchodilators
By Route of Administration Outlook (Revenue, USD Million; 2020-2033)
Oral
Inhaled
By Distribution Channel Outlook (Revenue, USD Million; 2020-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Regional Outlook (Revenue, USD Million; 2020-2033)
North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Benelux
Rest of Europe
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Rest of Latin America
Middle East and Africa
Saudi Arabia
UAE
South Africa
Turkey
Rest of MEA
Request For Customization Report@
Look Over transcripts provided by Emergen Research
Cystic Fibrosis Therapeutics Market Size@ /market-size
Cystic Fibrosis Therapeutics Market Share@ /market-share
Cystic Fibrosis Therapeutics Market Trends@ /market-trends
Cystic Fibrosis Therapeutics Regional Market Demand@ /regional-market-demand
Cystic Fibrosis Therapeutics Market Analysis@ /market-analysis
Eric Lee
Emergen Research
+ +91 90210 91709
...
Visit us on social media:
Facebook
X
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN21012025003118003196ID1109112476